Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Double-blind, Extension, Placebo-controlled Parallel Group Safety and Efficacy Trial of BI 10773 (10 and 25mg Once Daily) and Sitagliptin (100mg Once Daily) Given for Minimum 76 Weeks (Incl. 24 Weeks of Preceding Trial) as Monotherapy or With Different Back-ground Therapies in Patients With Type 2 Diabetes Mellitus Previously Completing Trial 1245.19, 1245.20 or 1245.23
Brief Summary: This study will investigate the efficacy and long term safety and tolerability of BI 10773 in type 2 diabetic patients.


Options:
A: Arm Label: Lira 1.8 mg; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 1.8 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: Dapagliflozin; Type: EXPERIMENTAL; Interventions: Drug: Dapagliflozin 10 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo tablet | Intervention Type: DRUG; Name: Dapagliflozin 10 mg; Assigned to Arm(s): Dapagliflozin | Intervention Type: DRUG; Name: Placebo tablet; Assigned to Arm(s): Placebo
C: Arm Label: Dapagliflozin; Type: EXPERIMENTAL; Interventions: Drug: Dapagliflozin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dapagliflozin; Assigned to Arm(s): Dapagliflozin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: BI 10773 low (drug naive); Type: EXPERIMENTAL; Interventions: Drug: BI 10773, Drug: Placebo | Arm Label: BI 10773 high (drug naive); Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: BI 10773 | Arm Label: Placebo (drug naive); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Sitagliptin 100mg (drug naive); Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: Sitagliptin 100mg | Arm Label: BI 10773 low (pioglitazone); Type: EXPERIMENTAL; Interventions: Drug: BI 10773, Drug: Placebo | Arm Label: BI 10773 high (pioglitazone); Type: EXPERIMENTAL; Interventions: Drug: BI 10773, Drug: Placebo | Arm Label: Placebo (pioglitazone); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: BI 10773 low (metformin); Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: BI 10773 | Arm Label: BI 10773 high (metformin); Type: EXPERIMENTAL; Interventions: Drug: BI 10773, Drug: Placebo | Arm Label: Placebo (metformin); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: BI 10773 low (metformin+sulfonylurea); Type: EXPERIMENTAL; Interventions: Drug: BI 10773, Drug: Placebo | Arm Label: BI 10773 high (metformin+sulfonylurea); Type: EXPERIMENTAL; Interventions: Drug: BI 10773, Drug: Placebo | Arm Label: Placebo (metformin+sulfonylurea); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BI 10773; Assigned to Arm(s): BI 10773 low (drug naive) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (drug naive) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sitagliptin 100mg (drug naive) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (drug naive) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BI 10773 low (metformin) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (drug naive) | Intervention Type: DRUG; Name: BI 10773; Assigned to Arm(s): BI 10773 high (metformin) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (pioglitazone) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sitagliptin 100mg (drug naive) | Intervention Type: DRUG; Name: BI 10773; Assigned to Arm(s): BI 10773 low (pioglitazone) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (metformin) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BI 10773 low (pioglitazone) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BI 10773 high (drug naive) | Intervention Type: DRUG; Name: BI 10773; Assigned to Arm(s): BI 10773 low (metformin) | Intervention Type: DRUG; Name: BI 10773; Assigned to Arm(s): BI 10773 low (metformin+sulfonylurea) | Intervention Type: DRUG; Name: BI 10773; Assigned to Arm(s): BI 10773 high (drug naive) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (metformin) | Intervention Type: DRUG; Name: BI 10773; Assigned to Arm(s): BI 10773 high (metformin+sulfonylurea) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BI 10773 high (metformin+sulfonylurea) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (pioglitazone) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BI 10773 low (drug naive) | Intervention Type: DRUG; Name: Sitagliptin 100mg; Assigned to Arm(s): Sitagliptin 100mg (drug naive) | Intervention Type: DRUG; Name: BI 10773; Assigned to Arm(s): BI 10773 high (pioglitazone) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BI 10773 high (pioglitazone) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (metformin+sulfonylurea) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BI 10773 high (drug naive) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (metformin+sulfonylurea) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BI 10773 high (metformin) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BI 10773 low (metformin+sulfonylurea) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BI 10773 low (drug naive)

Answer: D